AI (Re)Defining Pharmaceutical Exclusivities

Abstract

Biotechnology Law ReportVol. 41, No. 1 Original ArticlesAI (Re)Defining Pharmaceutical Exclusivitiesis corrected byCorrection to: AI (Re)Defining Pharmaceutical Exclusivities, by Jonathan Kimball and Srividhya Ragavan, Biotechnol Law Rep 2022;41(1):23–29; doi: 10.1089/blr.2021.29257.srBy Jonathan Kimball and Srividhya RagavanBy Jonathan KimballJonathan Kimball has worked for 15 years on pharmaceutical policy issues impacting both the brand and generic industries. Srividhya Ragavan is a Professor of Law and Faculty Director of the India Program at Texas A&M School of Law in Fort Worth, Texas, USA. A version of this argument was presented at the University of the Pacific Law School and a part of that published with Sofia Vegas as Reconsidering the Rationale for the Duration of Data Exclusivity, 51 U. Pac. L. Rev. 525 (2020). The views expressed in this article are those of the authors and do not necessarily represent the organizations for which they work.Search for more papers by this author and Srividhya RagavanE-mail Address: ragavan.sri@law.tamu.eduJonathan Kimball has worked for 15 years on pharmaceutical policy issues impacting both the brand and generic industries. Srividhya Ragavan is a Professor of Law and Faculty Director of the India Program at Texas A&M School of Law in Fort Worth, Texas, USA. A version of this argument was presented at the University of the Pacific Law School and a part of that published with Sofia Vegas as Reconsidering the Rationale for the Duration of Data Exclusivity, 51 U. Pac. L. Rev. 525 (2020). The views expressed in this article are those of the authors and do not necessarily represent the organizations for which they work.Search for more papers by this authorPublished Online:11 Feb 2022https://doi.org/10.1089/blr.2021.29257.srAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsRelated articlesCorrection to: AI (Re)Defining Pharmaceutical Exclusivities, by Jonathan Kimball and Srividhya Ragavan, Biotechnol Law Rep 2022;41(1):23–29; doi: 10.1089/blr.2021.29257.sr12 Apr 2022Biotechnology Law Report Volume 41Issue 1Feb 2022 InformationCopyright 2022, Mary Ann Liebert, Inc., publishersTo cite this article:By Jonathan Kimball and Srividhya Ragavan.AI (Re)Defining Pharmaceutical Exclusivities.Biotechnology Law Report.Feb 2022.23-29.http://doi.org/10.1089/blr.2021.29257.srPublished in Volume: 41 Issue 1: February 11, 2022Online Ahead of Print:February 1, 2022Keywordsartificial intelligencedata exclusivitypharmaceuticalsperiod of exclusivityFDAbiologicsPDF download